The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.
In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...
LLY's Zepbound shows better weight loss than NVO's Wegovy in a study. FDA updates for MRK, RHHBY, JNJ and AZN drugs grab ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Major names include Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound. Eli Lilly alleged it relies on a ...
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...
The purchase price of the facility was not disclosed, but Lilly says its new $3 billion investment – part of $23 billion ...
Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start ...
Research shows an average weight loss of just 5% could save an annual $153bn in medical fees and lost productivity.
Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating on December 2.Don't Miss our ...
However, Englander's interest isn't limited to tech stocks. The billionaire recently bought an obesity drug stock that could soar nearly 20% over the next 12 months, according to Wall Street.
The company's s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world ...